

GI/PANCREAS/NET/LIVER CANCER SPORE INVESTIGATOR'S MEETING

The GI/Pancreas/NET/Liver Cancer SPORE Investigators' Meeting in Phoenix, AZ, was a great success. With 24 in person speakers and 12 virtual speakers addressing the following critical areas: tumor metabolism, cancer immunology and immune microenvironment, precision therapy, and precursor lesions, early detection, and interception.

Mayo Clinic would like to thank everyone that participated.

FEATURES

Dr. Gores: Pioneering care for liver disease



Gregory Gores, M.D., (Project 2) Kinney Executive Dean of Research, has made enormous, unique, and precedent-setting contributions to patient care, discovery, application research and education.

Dr. Gores was recently honored with the 2023 Mayo Clinic Alumni Association Professional Achievement Award. Among his many accomplishments, he says he's most proud of the people he's helped train and the success they've achieved. Throughout his career, Dr. Gores has mentored and helped to launch the careers of more than 80 fellows, 73% of whom now work in academic medicine around the world. For his efforts, Dr. Gores previously received an Outstanding Mentorship Award from the Department of Internal Medicine at Mayo Clinic in Rochester and a Mentorship Award from the American Gastroenterological Association. He is a past program director of the Transplant Hepatology Fellowship Program at Mayo Clinic in Rochester. [Read more.](#)

Research fuels advances in bile duct cancer care



Bile duct cancer, also known as cholangiocarcinoma, forms in the thin tubes that carry bile from your liver to your gallbladder and small intestine. Though relatively rare, cholangiocarcinoma is often diagnosed in later stages, making it more difficult to treat, and cases in the U.S. are increasing.

In a [review article](#) published in Nature Reviews Clinical Oncology in 2023, lead author Sumera I. Ilyas, M.B.B.S., and co-authors share advances in diagnosing, staging and treating bile duct cancer. Dr. Ilyas is a Mayo Clinic physician-scientist and a transplant hepatologist whose research focuses on the immunobiology of liver cancer. [Read more.](#)

Anna-Maria and Stephen Kellen Building Opens



The Anna-Maria and Stephen Kellen Building opened its doors on December 13, 2023, in Rochester, Minnesota, welcoming visitors as well as the scientists and staff who support Mayo Clinic's research efforts. The 11-floor, 176,000-square-foot facility is where researchers will work to address the unmet needs of patients through scientific advancements that impact patient care, leading to better outcomes and improved quality of life in Minnesota and beyond. [Read more.](#)

COMMUNITY ENGAGEMENT AND DIVERSITY COUNCIL

TOPIC: BLACK HISTORY MONTH - LIVER CANCER PATIENT STORIES & RESEARCH


Featuring Medical Experts & Personal Stories

**Thursday, February 22nd
3:00 – 4:30pm CST**

IN PERSON AND VIRTUAL OPTIONS

Barbershop Social Services 3270
19th Street NW
Suite 207
Rochester, MN 55901
*Light refreshments served from 2:30-3:00pm
CST*

[LINK TO REGISTER](#)



MAYO CLINIC | Comprehensive Cancer Center

Cancer Conversations

TOPIC: BLACK HISTORY MONTH - LIVER CANCER PATIENT STORIES & RESEARCH
Featuring Medical Experts & Personal Stories

LINK TO REGISTER:
<https://molve.zoom.us/j/96124242424?pwd=MTI1L0Y5RDZlMjUyVjZkVzZGZl>

Thursday, February 22nd 3:00 – 4:30pm CST

IN PERSON AND VIRTUAL OPTIONS
Barbershop Social Services
3270 19th Street NW
Suite 207
Rochester, MN 55901
Light refreshments served from 2:30-3:00pm CST

IN PARTNERSHIP WITH:

NAACP Rochester Branch | **paat ja** | **Barbershop Talks**

Learn more by e-mailing:
MCDDCOE@mayo.edu

Our SPORE continues to engage our patient communities in the catchment areas around Mayo Clinic-Rochester (Midwest), Mayo Clinic-FL, and Mayo Clinic-AZ via multiple initiatives.

Please contact Dr. Lewis Roberts roberts.lewis@mayo.edu or Dr. Lionel Kankeu Fonkoua KankeuFonkoua.Lionel@mayo.edu to get involved!

We value the participation of SPORE investigators, administrators, and especially our Patient Advocates.

OPPORTUNITIES AND STRATEGIES FOR COMMUNITY ENGAGEMENT MEETING

Opportunities and Strategies for Community Engagement meeting previously held on the second Monday of every month from 11:30-12:00 CST is moving to the second Thursday of every month from 12:00-12:30 pm CST. The next meeting is Thursday, March 14, 2024, 12:00-12:30 p.m. CST.

RECENT PUBLICATIONS

Articles were identified through a PubMed search of Mayo investigators

[Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.](#)

Wang Y, Wang X, Bai B, Shaha A, He X, He Y, Ye Z, **Shah VH**, Kang N. *Hepatology* (IF: 17.43; Q1). 2024 Jan 24. doi: 10.1097/HEP.0000000000000763. Online ahead of print. PMID: 38271673

RECENT PUBLICATIONS (CONTINUED)[Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.](#)

Fogliati A, Zirona A, Fiorentini G, Adjei S, Amro A, Starlinger PP, Grotz TE, **Warner SG, Smoot RL**, Thiels CA, Kendrick ML, **Cleary SP**, Truty MJ.

Ann Surg Oncol. 2024 Feb 6. doi: 10.1245/s10434-023-14875-5. Epub ahead of print. PMID: 38319513.

[APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients.](#)

Aslam FN, Loveday TA, Junior PLSU, Truty M, **Smoot R**, Bekaii-Saab T, Stucky CC, Babiker H, **Borad MJ.** *Ann Gastroenterol.* 2024 Jan-Feb;37(1):95-103. doi: 10.20524/aog.2024.0845. Epub 2023 Dec 20. PMID: 38223247; PMCID: PMC10785017.

[Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma.](#)

Loeuillard EJ, Li B, Stumpf HE, Yang J, Willhite JR, Tomlinson JL, Rohakhtar FR, Simon VA, Graham RP, **Smoot RL**, Dong H, Ilyas SI.

Cell Mol Gastroenterol Hepatol. 2024 Jan 14:S2352-345X(24)00005-5. doi: 10.1016/j.jcmgh.2024.01.006. Epub ahead of print. PMID: 38219900.

[Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.](#)

Emiloju OE, Yin J, Koubek E, Reid JM, **Borad MJ**, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, **Gores GJ, Roberts LR**, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA.

Invest New Drugs. 2024 Jan 25. doi: 10.1007/s10637-024-01420-8. Epub ahead of print. PMID: 38270822.

[SerpinB3/4 Expression Is Associated with Poor Prognosis in Patients with Cholangiocarcinoma.](#)

Martini A, Prasai K, Zemla TJ, Ahmed FY, Elnagar MB, Giama NH, Guzzardo V, Biasiolo A, Fassan M, Yin J, Pontisso P, **Roberts LR.**

Cancers (Basel). 2024 Jan 3;16(1):225. doi: 10.3390/cancers16010225. PMID: 38201652; PMCID: PMC10778206.

[Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.](#)

Park JE, Nguyen VH, Tsai PC, Toyoda H, Leong J, Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, **Roberts LR**, Schwartz ME, Kumada T, Yu ML, Nguyen MH.

Aliment Pharmacol Ther. 2024 Jan 3. doi: 10.1111/apt.17863. Epub ahead of print. PMID: 38173278.

[GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.](#)

Neumayer C, Ng D, Requena D, Jiang CS, Qureshi A, Vaughan R, Prakash TP, Revenko A, **Simon SM.** *Mol Ther.* 2024 Jan 3;32(1):140-151. doi: 10.1016/j.ymthe.2023.11.012. Epub 2023 Nov 21. PMID: 37980543; PMCID: PMC10787139.



REMINDERS

Acknowledge the HBC SPORE **P50 CA210964** in your abstracts, presentations, and publications.

LIVER SPORE CONTACTS

Mark McNiven, Ph.D., SPORE Director

Mike Torbenson, M.D.

Co-Director, Biospecimen & Pathology Core

John Henley, Ph.D, Administrator

Amanda Bedard, Administrative Assistant

Lewis Roberts, M.B., Ch.B., Ph.D., SPORE Co-Director

Qian Shi, Ph.D. and Chen Wang, Ph.D.

Co-Directors, Biostatistics and Bioinformatics Core

Fowsiyo Ahmed, M.B.B.S., Biospecimen Coordinator

Images used with permission